Phaseline

Targets › CBP

CBP (Histone lysine acetyltransferase CREBBP): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). (UniProt, Q92793)

Open in Phaseline: the race on CBP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Opna BioOPN-6602
EP300 and CBP bromodomain inhibitor
EP300, CBPPhase 1Relapsed Multiple MyelomaDec 2027

Conditions

Relapsed Multiple Myeloma (1)

Modalities

small molecule (1)

Companies

Opna Bio (1)

Related targets

EP300 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.